Executive summary
India regulates peptides under the Drugs and Cosmetics Act, 1940 (D&C Act) and the Drugs Rules, 1945. The CDSCO (Central Drugs Standard Control Organisation) and DCGI (Drugs Controller General of India) oversee drug approval and enforcement. India has a growing domestic peptide pharmaceutical manufacturing sector. The e-pharmacy regulatory framework remains draft since 2018.
Authorities and legal categories
CDSCO: central drug approval, clinical trial oversight, import licensing.
DCGI: head of CDSCO.
State Licensing Authorities: manufacturing and sale licensing, enforcement for e-pharmacies.
Key instruments:
Drugs and Cosmetics Act, 1940.
Drugs Rules, 1945.
New Drugs and Clinical Trials Rules, 2019 (NDCT Rules).
Drugs and Cosmetics (Amendment) Act, 2008 (Act 26 of 2008).
Approved medicines
Approved peptide medicines include GLP-1 receptor agonists (semaglutide/Ozempic, liraglutide, tirzepatide/Mounjaro), insulin analogues, teriparatide, octreotide, leuprolide, and desmopressin. Domestic semaglutide manufacturing was approved in 2025–2026 (Cipla, Sun Pharma, Dr Reddy's among applicants).
Source: CDSCO Drug Register, https://cdsco.gov.in
Investigational use
Clinical trials must comply with the NDCT Rules, 2019. Regulatory approval from CDSCO and ethics committee clearance are required. Form 11 allows import of small research quantities of new drugs without bioavailability/ bioequivalence data.
Compounding/manufacturing
Pharmacy compounding in India generally follows the D&C Act provisions for extemporaneous preparation. The scale of compounding is far smaller than in Western jurisdictions. Most peptides are manufactured products requiring manufacturing licence and drug approval.
Import
Unapproved drugs require CDSCO import registration.
Form CT-25 / NDCT Rules 86–88: this is not a general consumer pathway. The cited rules limit the route to a government hospital or government medical institution, for specified serious conditions, where the drug is approved in its country of origin, with Central Licensing Authority review. The full current rule and form control every eligibility and quantity limit.
Personal import of unapproved drugs is not permitted.
Research quantities can be imported under Form 11 for R&D purposes, not for consumer sale.
Online sale
The Draft e-Pharmacy Rules (2018) remain unfinalised as of August 2026.
Enforcement is via State Licensing Authorities under the D&C Act.
Online sale of prescription-only peptide medicines is legally restricted to registered pharmacies with a valid prescription. Many unregistered websites operate in a grey area.
Research-use-only products
India does not recognise "research use only" as an exemption from drug regulation. Products marketed with therapeutic claims are drugs requiring approval. Research reagents for institutional use are separate.
Enforcement examples and uncertainty
CDSCO has not specifically targeted "research peptide" vendors at the same scale as US/EU regulators.
Uncertainty: the unfinalised e-pharmacy rules create enforcement gaps for online peptide sales. State-level enforcement is uneven.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Primary sources
CDSCO. https://cdsco.gov.in
Drugs and Cosmetics Act, 1940. https://cdsco.gov.in (legislation section).
NDCT Rules, 2019. https://cdsco.gov.in
Form 11 / Form CT-25 guidance. https://cdsco.gov.in (import/export section).